ds logo

Tresiba® demonstrated no increased risk of major cardiovascular events

Posted on

Tresiba® demonstrated no increased danger of major cardiovascular (CV) events and vital reduction in rates of extreme hypoglycaemia in comparison with insulin glargine U100 within the DEVOTE trial, says a press release.

DEVOTE is a long-term, multi-national, randomised, double-blind and event-driven trial carried out to verify the CV safety of Tresiba® (insulin degludec) compared to insulin glargine U100.

In the trial, 7,637 individuals (Tresiba®: n=3,818, insulin glargine U100: n=3,819) with sort 2 diabetes at high danger of CV illness have been randomised to remedy with both Tresiba® or insulin glargine U100 in vial in addition to normal of care.

Other articles you might like;

Leave a Reply

Your email address will not be published. Required fields are marked *